Steve Ubl has led AdvaMed for 10 years, raising profile of device industry on Capitol Hill and executing well-regarded public relations campaign of the kind the drug industry might need as it enters political maelstrom on pricing.

If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.

Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.